Compare HFFG & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HFFG | ACRV |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | United States |
| Employees | 960 | N/A |
| Industry | Food Distributors | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.7M | 68.5M |
| IPO Year | 2016 | 2022 |
| Metric | HFFG | ACRV |
|---|---|---|
| Price | $1.51 | $1.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.00 | ★ $11.67 |
| AVG Volume (30 Days) | 126.6K | ★ 460.7K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.65 | 15.13 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $1,228,282,000.00 | N/A |
| Revenue This Year | $5.59 | N/A |
| Revenue Next Year | $2.24 | $568.17 |
| P/E Ratio | $75.00 | ★ N/A |
| Revenue Growth | ★ 2.21 | N/A |
| 52 Week Low | $1.38 | $1.20 |
| 52 Week High | $3.86 | $3.56 |
| Indicator | HFFG | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 38.28 | 42.06 |
| Support Level | $1.40 | $1.38 |
| Resistance Level | $2.30 | $2.20 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 13.46 | 19.46 |
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, frozen and dry food, and non-food products to Asian restaurants and other foodservice customers throughout the United States. The company's business consists of one operating segment: HF Group, which operates solely in the United States. The company's product list consists of Meat, Poultry & Seafood, Sauces & Oils, Takeout Items (Boxes, Chopsticks & Utensils), Raw Ingredients (Flour, Cornstarch, Spices), Cleaning Supplies, and Rice & Grains.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.